The Efficacy and Prognostic Factors of the Combination of TACE and Apatinib for the Treatment of BCLC Stage C Hepatocellular Carcinoma
Objective: Apatinib is a inhibitor of vascular endothelial growth factor receptor-2. To explore the efficacy and prognostic factors of transarterial chemoembolization (TACE) combined with apatinib in the treatment of Barcelona Clinic Liver Cancer stage C (BCLC C) hepatocellular carcinoma (HCC).Metho...
Guardado en:
Autores principales: | , , , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/6bb532298dbb4bf9b78cb6cca1a694df |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:6bb532298dbb4bf9b78cb6cca1a694df |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:6bb532298dbb4bf9b78cb6cca1a694df2021-12-03T05:12:15ZThe Efficacy and Prognostic Factors of the Combination of TACE and Apatinib for the Treatment of BCLC Stage C Hepatocellular Carcinoma2296-858X10.3389/fmed.2021.774345https://doaj.org/article/6bb532298dbb4bf9b78cb6cca1a694df2021-12-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fmed.2021.774345/fullhttps://doaj.org/toc/2296-858XObjective: Apatinib is a inhibitor of vascular endothelial growth factor receptor-2. To explore the efficacy and prognostic factors of transarterial chemoembolization (TACE) combined with apatinib in the treatment of Barcelona Clinic Liver Cancer stage C (BCLC C) hepatocellular carcinoma (HCC).Methods: Clinical data of 146 HCC patients with BCLC stage C admitted to our hospital were collected and analyzed retrospectively, of which 76 cases were treated with TACE combined with apatinib (TACE-apatinib) and 70 with TACE alone. The tumor response, survival time, and adverse events were compared between the two groups, and the factors affecting the prognosis were analyzed.Results: The objective response rate (ORR) and disease control rate (DCR) in the TACE-apatinib group were higher than in the TACE-alone group (ORR: 42.10 vs. 25.71%, P = 0.03; DCR: 84.21 vs. 55.71%, P = 0.001). The median time to progression (TTP) and overall survival (OS) in the TACE-apatinib group were longer than in the TACE-alone group (TTP: 5.5 vs. 3.7 months, P = 0.02; OS: 10.0 vs. 6.2 months, P = 0.01). Univariate and multivariate Cox regression analysis showed that tumor size, Child-Pugh class, and the presence of the portal vein tumor thrombus affect the prognosis of patients. Subgroup analysis revealed that TACE-apatinib therapy resulted in a higher OS in patients with tumor size <10 cm, without portal vein tumor thrombus, and with Child-Pugh class A (P < 0.05). The likelihood of adverse events (hand-foot syndrome, hypertension, oral ulcer) was significantly higher in the increased in the TACE-apatinib group than in the TACE alone group (P < 0.05).Conclusion: TACE-apatinib is an effective and safe method for the treatment of BCLC stage C HCC. Tumor size, Child-Pugh class, and portal vein tumor thrombus affect survival time in HCC patients with BCLC stage C.Shun LiuShun LiuKai-Cai LiuWei-Fu LvWei-Fu LvDong LuXian-Hai ZhuBo JiangYu-Lin TanGuo-Xiang WangFrontiers Media S.A.articlehepatocellular carcinomaTACEapatinibefficacyprognostic factorsMedicine (General)R5-920ENFrontiers in Medicine, Vol 8 (2021) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
hepatocellular carcinoma TACE apatinib efficacy prognostic factors Medicine (General) R5-920 |
spellingShingle |
hepatocellular carcinoma TACE apatinib efficacy prognostic factors Medicine (General) R5-920 Shun Liu Shun Liu Kai-Cai Liu Wei-Fu Lv Wei-Fu Lv Dong Lu Xian-Hai Zhu Bo Jiang Yu-Lin Tan Guo-Xiang Wang The Efficacy and Prognostic Factors of the Combination of TACE and Apatinib for the Treatment of BCLC Stage C Hepatocellular Carcinoma |
description |
Objective: Apatinib is a inhibitor of vascular endothelial growth factor receptor-2. To explore the efficacy and prognostic factors of transarterial chemoembolization (TACE) combined with apatinib in the treatment of Barcelona Clinic Liver Cancer stage C (BCLC C) hepatocellular carcinoma (HCC).Methods: Clinical data of 146 HCC patients with BCLC stage C admitted to our hospital were collected and analyzed retrospectively, of which 76 cases were treated with TACE combined with apatinib (TACE-apatinib) and 70 with TACE alone. The tumor response, survival time, and adverse events were compared between the two groups, and the factors affecting the prognosis were analyzed.Results: The objective response rate (ORR) and disease control rate (DCR) in the TACE-apatinib group were higher than in the TACE-alone group (ORR: 42.10 vs. 25.71%, P = 0.03; DCR: 84.21 vs. 55.71%, P = 0.001). The median time to progression (TTP) and overall survival (OS) in the TACE-apatinib group were longer than in the TACE-alone group (TTP: 5.5 vs. 3.7 months, P = 0.02; OS: 10.0 vs. 6.2 months, P = 0.01). Univariate and multivariate Cox regression analysis showed that tumor size, Child-Pugh class, and the presence of the portal vein tumor thrombus affect the prognosis of patients. Subgroup analysis revealed that TACE-apatinib therapy resulted in a higher OS in patients with tumor size <10 cm, without portal vein tumor thrombus, and with Child-Pugh class A (P < 0.05). The likelihood of adverse events (hand-foot syndrome, hypertension, oral ulcer) was significantly higher in the increased in the TACE-apatinib group than in the TACE alone group (P < 0.05).Conclusion: TACE-apatinib is an effective and safe method for the treatment of BCLC stage C HCC. Tumor size, Child-Pugh class, and portal vein tumor thrombus affect survival time in HCC patients with BCLC stage C. |
format |
article |
author |
Shun Liu Shun Liu Kai-Cai Liu Wei-Fu Lv Wei-Fu Lv Dong Lu Xian-Hai Zhu Bo Jiang Yu-Lin Tan Guo-Xiang Wang |
author_facet |
Shun Liu Shun Liu Kai-Cai Liu Wei-Fu Lv Wei-Fu Lv Dong Lu Xian-Hai Zhu Bo Jiang Yu-Lin Tan Guo-Xiang Wang |
author_sort |
Shun Liu |
title |
The Efficacy and Prognostic Factors of the Combination of TACE and Apatinib for the Treatment of BCLC Stage C Hepatocellular Carcinoma |
title_short |
The Efficacy and Prognostic Factors of the Combination of TACE and Apatinib for the Treatment of BCLC Stage C Hepatocellular Carcinoma |
title_full |
The Efficacy and Prognostic Factors of the Combination of TACE and Apatinib for the Treatment of BCLC Stage C Hepatocellular Carcinoma |
title_fullStr |
The Efficacy and Prognostic Factors of the Combination of TACE and Apatinib for the Treatment of BCLC Stage C Hepatocellular Carcinoma |
title_full_unstemmed |
The Efficacy and Prognostic Factors of the Combination of TACE and Apatinib for the Treatment of BCLC Stage C Hepatocellular Carcinoma |
title_sort |
efficacy and prognostic factors of the combination of tace and apatinib for the treatment of bclc stage c hepatocellular carcinoma |
publisher |
Frontiers Media S.A. |
publishDate |
2021 |
url |
https://doaj.org/article/6bb532298dbb4bf9b78cb6cca1a694df |
work_keys_str_mv |
AT shunliu theefficacyandprognosticfactorsofthecombinationoftaceandapatinibforthetreatmentofbclcstagechepatocellularcarcinoma AT shunliu theefficacyandprognosticfactorsofthecombinationoftaceandapatinibforthetreatmentofbclcstagechepatocellularcarcinoma AT kaicailiu theefficacyandprognosticfactorsofthecombinationoftaceandapatinibforthetreatmentofbclcstagechepatocellularcarcinoma AT weifulv theefficacyandprognosticfactorsofthecombinationoftaceandapatinibforthetreatmentofbclcstagechepatocellularcarcinoma AT weifulv theefficacyandprognosticfactorsofthecombinationoftaceandapatinibforthetreatmentofbclcstagechepatocellularcarcinoma AT donglu theefficacyandprognosticfactorsofthecombinationoftaceandapatinibforthetreatmentofbclcstagechepatocellularcarcinoma AT xianhaizhu theefficacyandprognosticfactorsofthecombinationoftaceandapatinibforthetreatmentofbclcstagechepatocellularcarcinoma AT bojiang theefficacyandprognosticfactorsofthecombinationoftaceandapatinibforthetreatmentofbclcstagechepatocellularcarcinoma AT yulintan theefficacyandprognosticfactorsofthecombinationoftaceandapatinibforthetreatmentofbclcstagechepatocellularcarcinoma AT guoxiangwang theefficacyandprognosticfactorsofthecombinationoftaceandapatinibforthetreatmentofbclcstagechepatocellularcarcinoma AT shunliu efficacyandprognosticfactorsofthecombinationoftaceandapatinibforthetreatmentofbclcstagechepatocellularcarcinoma AT shunliu efficacyandprognosticfactorsofthecombinationoftaceandapatinibforthetreatmentofbclcstagechepatocellularcarcinoma AT kaicailiu efficacyandprognosticfactorsofthecombinationoftaceandapatinibforthetreatmentofbclcstagechepatocellularcarcinoma AT weifulv efficacyandprognosticfactorsofthecombinationoftaceandapatinibforthetreatmentofbclcstagechepatocellularcarcinoma AT weifulv efficacyandprognosticfactorsofthecombinationoftaceandapatinibforthetreatmentofbclcstagechepatocellularcarcinoma AT donglu efficacyandprognosticfactorsofthecombinationoftaceandapatinibforthetreatmentofbclcstagechepatocellularcarcinoma AT xianhaizhu efficacyandprognosticfactorsofthecombinationoftaceandapatinibforthetreatmentofbclcstagechepatocellularcarcinoma AT bojiang efficacyandprognosticfactorsofthecombinationoftaceandapatinibforthetreatmentofbclcstagechepatocellularcarcinoma AT yulintan efficacyandprognosticfactorsofthecombinationoftaceandapatinibforthetreatmentofbclcstagechepatocellularcarcinoma AT guoxiangwang efficacyandprognosticfactorsofthecombinationoftaceandapatinibforthetreatmentofbclcstagechepatocellularcarcinoma |
_version_ |
1718373935583592448 |